ONCOCYTE CORP (OCX) Stock Fundamental Analysis
USA - NASDAQ:OCX - US68235C2061 - Common Stock
3.2 USD
+0.47 (+17.22%)
3.17 USD
-0.03 (-0.94%)
We assign a fundamental rating of 2 out of 10 to OCX. OCX was compared to 535 industry peers in the Biotechnology industry. OCX may be in some trouble as it scores bad on both profitability and health. OCX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year OCX has reported negative net income.
OCX had a negative operating cash flow in the past year.
OCX had negative earnings in each of the past 5 years.
In the past 5 years OCX always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -96.52%, OCX is not doing good in the industry: 75.27% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -570.19%, OCX is doing worse than 79.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -96.52% | ||
| ROE | -570.19% | ||
| ROIC | N/A |
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 52.56%, OCX is doing good in the industry, outperforming 77.24% of the companies in the same industry.
In the last couple of years the Gross Margin of OCX has declined.
OCX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 52.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
2. Health
2.1 Basic Checks
OCX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OCX has been increased compared to 1 year ago.
OCX has more shares outstanding than it did 5 years ago.
OCX has a worse debt/assets ratio than last year.
2.2 Solvency
OCX has an Altman-Z score of -7.51. This is a bad value and indicates that OCX is not financially healthy and even has some risk of bankruptcy.
OCX's Altman-Z score of -7.51 is on the low side compared to the rest of the industry. OCX is outperformed by 69.00% of its industry peers.
OCX has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
OCX has a Debt to Equity ratio of 0.05. This is in the lower half of the industry: OCX underperforms 62.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.51 |
ROIC/WACCN/A
WACC8.92%
2.3 Liquidity
OCX has a Current Ratio of 3.75. This indicates that OCX is financially healthy and has no problem in meeting its short term obligations.
OCX's Current ratio of 3.75 is in line compared to the rest of the industry. OCX outperforms 43.01% of its industry peers.
A Quick Ratio of 3.70 indicates that OCX has no problem at all paying its short term obligations.
OCX's Quick ratio of 3.70 is in line compared to the rest of the industry. OCX outperforms 44.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.7 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 31.19% over the past year.
The Revenue has grown by 178.48% in the past year. This is a very strong growth!
OCX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.09% yearly.
EPS 1Y (TTM)31.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.99%
Revenue 1Y (TTM)178.48%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%1114.77%
3.2 Future
OCX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.86% yearly.
The Revenue is expected to grow by 197.76% on average over the next years. This is a very strong growth
EPS Next Y78.19%
EPS Next 2Y33.55%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue Next Year508.91%
Revenue Next 2Y196.65%
Revenue Next 3Y197.76%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
OCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as OCX's earnings are expected to grow with 21.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.55%
EPS Next 3Y21.86%
5. Dividend
5.1 Amount
No dividends for OCX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.2
+0.47 (+17.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners56.3%
Inst Owner Change0%
Ins Owners0.97%
Ins Owner Change0%
Market Cap91.52M
Revenue(TTM)3.84M
Net Income(TTM)-58.26M
Analysts75
Price Target5.53 (72.81%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-178.01%
Min EPS beat(2)-347.17%
Max EPS beat(2)-8.85%
EPS beat(4)1
Avg EPS beat(4)-110.58%
Min EPS beat(4)-347.17%
Max EPS beat(4)36.24%
EPS beat(8)3
Avg EPS beat(8)-69.43%
EPS beat(12)6
Avg EPS beat(12)-56.88%
EPS beat(16)8
Avg EPS beat(16)-44.6%
Revenue beat(2)2
Avg Revenue beat(2)1470.69%
Min Revenue beat(2)1371.29%
Max Revenue beat(2)1570.08%
Revenue beat(4)2
Avg Revenue beat(4)707.66%
Min Revenue beat(4)-67.67%
Max Revenue beat(4)1570.08%
Revenue beat(8)4
Avg Revenue beat(8)355.12%
Revenue beat(12)4
Avg Revenue beat(12)213.18%
Revenue beat(16)5
Avg Revenue beat(16)144.09%
PT rev (1m)20.37%
PT rev (3m)31.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.05%
EPS NY rev (1m)-3.26%
EPS NY rev (3m)38.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)106.51%
Revenue NY rev (3m)195.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 23.81 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.96 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.53
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.13
BVpS0.36
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -96.52% | ||
| ROE | -570.19% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 52.56% | ||
| FCFM | N/A |
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 46.45% | ||
| Cap/Sales | 20.79% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.7 | ||
| Altman-Z | -7.51 |
F-Score4
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)44.29%
Cap/Depr(5y)100.36%
Cap/Sales(3y)166.07%
Cap/Sales(5y)140.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.99%
EPS Next Y78.19%
EPS Next 2Y33.55%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue 1Y (TTM)178.48%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%1114.77%
Revenue Next Year508.91%
Revenue Next 2Y196.65%
Revenue Next 3Y197.76%
Revenue Next 5YN/A
EBIT growth 1Y55.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.32%
EBIT Next 3Y10.61%
EBIT Next 5YN/A
FCF growth 1Y47.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.8%
OCF growth 3YN/A
OCF growth 5YN/A
ONCOCYTE CORP / OCX FAQ
Can you provide the ChartMill fundamental rating for ONCOCYTE CORP?
ChartMill assigns a fundamental rating of 2 / 10 to OCX.
Can you provide the valuation status for ONCOCYTE CORP?
ChartMill assigns a valuation rating of 1 / 10 to ONCOCYTE CORP (OCX). This can be considered as Overvalued.
Can you provide the profitability details for ONCOCYTE CORP?
ONCOCYTE CORP (OCX) has a profitability rating of 1 / 10.
Can you provide the financial health for OCX stock?
The financial health rating of ONCOCYTE CORP (OCX) is 3 / 10.